1
|
Debourdeau P, Gligorov J, Teixeira L,
Aletti M and Zammit C: Malignant cardiac tumors. Bull Cancer. 91
Suppl 3:S136–S146. 2004.(In French).
|
2
|
Lee KS, Kim GS, Jung Y, Jeong IS, Na KJ,
Oh BS, Ahn BH and Oh SG: Surgical resection of cardiac myxoma-a
30-year single institutional experience. J Cardiothorac Surg.
12:182017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mazzurin AV, Soboleva NI and Semenov BN:
Cardiac myxomas in children. Pediatriia. 46:50–53. 1967.(In
Russian). PubMed/NCBI
|
4
|
Butany J, Nair V, Naseemuddin A, Nair GM,
Catton C and Yau T: Cardiac tumors: Diagnosis and management.
Lancet Oncol. 6:219–228. 2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Reynen K: Cardiac myxomas. New Engl J Med.
333:1610–1617. 1995. View Article : Google Scholar : PubMed/NCBI
|
6
|
Jain D, Maleszewski JJ and Halushka MK:
Benign cardiac tumors and tumorlike conditions. Ann of Diagn
Pathol. 14:215–230. 2010. View Article : Google Scholar
|
7
|
Rupp GM, Heyman RA, Martinez AJ, Sekhar LN
and Jungreis CA: The pathology of metastatic cardiac myxoma. Am J
Clin Pathol. 91:221–227. 1989. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Garzon R, Fabbri M, Cimmino A, Calin GA
and Croce CM: MicroRNA expression and function in cancer. Trends
Mol Med. 12:580–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Onco. 6:590–610. 2012. View Article : Google Scholar
|
11
|
Chan SH, Wu CW, Li AF, Chi CW and Lin WC:
miR-21 microRNA expression in human gastric carcinomas and its
clinical association. Anticancer Res. 28:907–911. 2008.PubMed/NCBI
|
12
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhu Z, Qi Y, Ge A, Zhu Y, Xu K, Ji H, Shi
Z, Cui L and Zhou M: Comprehensive characterization of serum
microRNA profile in response to the emerging avian influenza A
(H7N9) virus infection in humans. Viruses. 6:1525–1539. 2014.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Krawczynski K, Najmula J, Bauersachs S and
Kaczmarek MM: MicroRNAome of porcine conceptuses and trophoblasts:
Expression profile of micrornas and their potential to regulate
genes crucial for establishment of pregnancy. Biol Reprod.
92:212015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Shen J, Xiao Z, Wu WK, Wang MH, To KF,
Chen Y, Yang W, Li MS, Shin VY, Tong JH, et al: Epigenetic
silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1
to promote Helicobacter pylori-induced gastric carcinogenesis.
Cancer Res. 75:754–765. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Ho CY, Bar E, Giannini C, Marchionni L,
Karajannis MA, Zagzag D, Gutmann DH, Eberhart CG and Rodriguez FJ:
MicroRNA profiling in pediatric pilocytic astrocytoma reveals
biologically relevant targets, including PBX3, NFIB, and METAP2.
Neuro Oncol. 15:69–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Li X, Peng B, Zhu X, Wang P, Xiong Y, Liu
H, Sun K, Wang H, Ou L, Wu Z, et al: Changes in related circular
RNAs following ERβ knockdown and the relationship to rBMSC
osteogenesis. Biochem Biophys Res Commun. 493:100–107. 2017.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:pp. 14863–14868. 1998;
View Article : Google Scholar : PubMed/NCBI
|
21
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Corsini LR, Bronte G, Terrasi M, Amodeo V,
Fanale D, Fiorentino E, Cicero G, Bazan V and Russo A: The role of
microRNAs in cancer: Diagnostic and prognostic biomarkers and
targets of therapies. Expert Opin Ther Targets. 16 Suppl
2:S103–S109. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhang J, Wang C and Xu H: miR-217
suppresses proliferation and promotes apoptosis in cardiac myxoma
by targeting Interleukin-6. Biochem Biophys Res Commun.
490:713–718. 2017. View Article : Google Scholar : PubMed/NCBI
|
24
|
Cao Q, Dong P and Wang Y, Zhang J, Shi X
and Wang Y: miR-218 suppresses cardiac myxoma proliferation by
targeting myocyte enhancer factor 2D. Oncol Rep. 33:2606–2612.
2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang
LL, Jiang W, Liu X, Cheng YK, He QM, et al: A four-miRNA signature
identified from genome-wide serum miRNA profiling predicts survival
in patients with nasopharyngeal carcinoma. Int J Cancer.
134:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Cong J, Liu R, Wang X, Jiang H and Zhang
Y: MiR-634 decreases cell proliferation and induces apoptosis by
targeting mTOR signaling pathway in cervical cancer cells. Artif
Cells Nanomed Biotechnol. 44:1694–1701. 2016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Peng X, Cao P, He D, Han S, Zhou J, Tan G,
Li W, Yu F, Yu J, Li Z and Cao K: MiR-634 sensitizes nasopharyngeal
carcinoma cells to paclitaxel and inhibits cell growth both in
vitro and in vivo. Int J Clin Exp Pathol. 7:6784–6791.
2014.PubMed/NCBI
|
28
|
Fujiwara N, Inoue J, Kawano T, Tanimoto K,
Kozaki K and Inazawa J: miR-634 activates the mitochondrial
apoptosis pathway and enhances chemotherapy-induced cytotoxicity.
Cancer Res. 75:3890–3901. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Wang B, Yang Z, Wang H, Cao Z, Zhao Y,
Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits
proliferation and invasion of breast cancer cells by targeting
RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Shang C, Zhang H, Guo Y, Hong Y, Liu Y and
Xue Y: MiR-320a down-regulation mediates bladder carcinoma invasion
by targeting ITGB3. Mol Biol Rep. 41:2521–2527. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhu Y, Zhang Y, Sui Z, Zhang Y, Liu M and
Tang H: USP14 de-ubiquitinates vimentin and miR-320a modulates
USP14 and vimentin to contribute to malignancy in gastric cancer
cells. Oncotarget. 8:48725–48736. 2017.PubMed/NCBI
|
32
|
Zhao H, Dong T, Zhou H, Wang L, Huang A,
Feng B, Quan Y, Jin R, Zhang W, Sun J, et al: miR-320a suppresses
colorectal cancer progression by targeting Rac1. Carcinogenesis.
35:886–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Qi X, Li J, Zhou C, Lv C and Tian M:
MicroRNA-320a inhibits cell proliferation, migration and invasion
by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett.
588:3732–3738. 2014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Yao J, Liang LH, Zhang Y, Ding J, Tian Q,
Li JJ and He XH: GNAI1 suppresses tumor cell migration and invasion
and is post-transcriptionally regulated by Mir-320a/c/d in
hepatocellular carcinoma. Cancer Biol Med. 9:234–241.
2012.PubMed/NCBI
|
35
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Xu G, Wu J, Zhou L, Chen B, Sun Z, Zhao F
and Tao Z: Characterization of the small RNA transcriptomes of
androgen dependent and independent prostate cancer cell line by
deep sequencing. PLoS One. 5:e155192010. View Article : Google Scholar : PubMed/NCBI
|
37
|
Xu Q, Dong QG, Sun LP, He CY and Yuan Y:
Expression of serum miR-20a-5p, let-7a, and miR-320a and their
correlations with pepsinogen in atrophic gastritis and gastric
cancer: A case-control study. BMC Clin Pathol. 13:112013.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Yang HP, Yu J, Wang L, Ding D, Zhang L,
Chu C, Chen Q, Xu Z, Zou Q and Liu X: miR-320a is an independent
prognostic biomarker for invasive breast cancer. Oncol Lett.
8:1043–1050. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Diakos C, Zhong S, Xiao Y, Zhou M,
Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M, Wiencke JK, et
al: TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and
miRNA-320a. Blood. 116:4885–4893. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Hummel R, Wang T, Watson DI, Michael MZ,
Van der Hoek M, Haier J and Hussey DJ: Chemotherapy-induced
modification of microRNA expression in esophageal cancer. Oncol
Rep. 26:1011–1017. 2011.PubMed/NCBI
|
41
|
Salendo J, Spitzner M, Kramer F, Zhang X,
Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et
al: Identification of a microRNA expression signature for
chemoradiosensitivity of colorectal cancer cells, involving
miRNAs-320a, −224, −132 and let7g. Radiother Oncol. 108:451–457.
2013. View Article : Google Scholar : PubMed/NCBI
|
42
|
Huo Y, Zhao Q, Wang C, Zhao F, Du Y and
Sun W: The involvement of myocyte enhancer factor 2D in regulating
tumor biology of cardiac myxoma. Tumour Biol. 37:5405–5411. 2016.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Yin Z, Zhao Y, Li H, Yan M, Zhou L, Chen C
and Wang DW: miR-320a mediates doxorubicin-induced cardiotoxicity
by targeting VEGF signal pathway. Aging (Albany NY). 8:192–207.
2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Kono T, Koide N, Hama Y, Kitahara H,
Nakano H, Suzuki J, Isobe M and Amano J: Expression of vascular
endothelial growth factor and angiogenesis in cardiac myxoma: A
study of fifteen patients. J Thorac Cardiovasc Surg. 119:101–107.
2000. View Article : Google Scholar : PubMed/NCBI
|
45
|
Amano J, Kono T, Wada Y, Zhang T, Koide N,
Fujimori M and Ito K: Cardiac myxoma: Its origin and tumor
characteristics. Ann Thorac Cardiovasc Surg. 9:215–221.
2003.PubMed/NCBI
|
46
|
Hannun YA and Obeid LM: Ceramide: An
intracellular signal for apoptosis. Trends Biochem Sci. 20:73–77.
1995. View Article : Google Scholar : PubMed/NCBI
|
47
|
Gulbins E: Regulation of death receptor
signaling and apoptosis by ceramide. Pharmacol Res. 47:393–399.
2003. View Article : Google Scholar : PubMed/NCBI
|
48
|
Kolesnick R and Fuks Z: Radiation and
ceramide-induced apoptosis. Oncogene. 22:5897–5906. 2003.
View Article : Google Scholar : PubMed/NCBI
|
49
|
Ogretmen B and Hannun YA: Biologically
active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer. 4:604–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
50
|
Modrak DE, Gold DV and Goldenberg DM:
Sphingolipid targets in cancer therapy. Mol Cancer Ther. 5:200–208.
2006. View Article : Google Scholar : PubMed/NCBI
|
51
|
Lin CF, Chen CL and Lin YS: Ceramide in
apoptotic signaling and anticancer therapy. Curr Med Chem.
13:1609–1616. 2006. View Article : Google Scholar : PubMed/NCBI
|
52
|
Mathias S, Peña LA and Kolesnick RN:
Signal transduction of stress via ceramide. Biochem J. 335:465–480.
1998. View Article : Google Scholar : PubMed/NCBI
|
53
|
Hannun YA and Obeid LM: Ceramide and the
eukaryotic stress response. Biochem Soc Trans. 25:1171–1175. 1997.
View Article : Google Scholar : PubMed/NCBI
|
54
|
Stoica BA, Movsesyan VA, Lea PM IV and
Faden AI: Ceramide-induced neuronal apoptosis is associated with
dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of
the mitochondrial-dependent intrinsic caspase pathway. Mol Cell
Neurosci. 22:365–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
55
|
Morad SAF and Cabot MC:
Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer.
13:51–65. 2013. View Article : Google Scholar : PubMed/NCBI
|